Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines

Academic Article

Abstract

  • The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
  • Digital Object Identifier (doi)

    Author List

  • Greenberg PL; Stone RM; Al-Kali A; Bennett JM; Borate U; Brunner AM; Chai-Ho W; Curtin P; De Castro CM; Joachim Deeg H
  • Start Page

  • 106
  • End Page

  • 117
  • Volume

  • 20
  • Issue

  • 2